|
Re: FDA news release on pertuzumab approval (perjeta)
Not withstanding the availability/production issues with this drug, does the FDA approval require that orignal early stage Her2+ patients first be tested to confirm their cancer is still Her2+ before receiving Perjeta? I ask this question since I believe I read here that sometimes the breast cancer can change its expression of the Her2 receptor either over or under as it progresses.--bird
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|